Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00398112 | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00402181 | An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 53 | Centocor, Inc.INDUSTRY | 2 | May 14, 2014 | clinicaltrials |
| NCT00303953 | PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 12, 2014 | clinicaltrials |
| NCT00431769 | An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma | completed | Phase 2 | 130 | Janssen-Cilag International NVINDUSTRY | 8 | May 12, 2014 | clinicaltrials |
| NCT01130194 | Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma(MasterPlan) | completed | Phase 2 | 29 | St. Louis UniversityOTHER | 1 | May 12, 2014 | clinicaltrials |
| NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 8, 2014 | clinicaltrials |
| NCT00901225 | Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone(UPFRONT) | completed | Phase 3 | 502 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 1, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT01026701 | Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. | completed | — | 104 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Apr 28, 2014 | clinicaltrials |
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2014 | clinicaltrials |
| NCT01105403 | Exploratory Study on POL6326 in Stem Cell Mobilization | completed | Phase 2 | 21 | Polyphor Ltd.INDUSTRY | 1 | Apr 23, 2014 | clinicaltrials |
| NCT01161511 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | completed | Phase 1 | 27 | Xencor, Inc.INDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT00109967 | CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 71 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2014 | clinicaltrials |
| NCT01220375 | PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma(PAV) | completed | Phase 2 | 44 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00482846 | Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | completed | Phase 1 | 38 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 15, 2014 | clinicaltrials |
| NCT00847639 | Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma(07-REV) | completed | Phase 2 | 30 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Apr 4, 2014 | clinicaltrials |
| NCT00033267 | CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2014 | clinicaltrials |
| NCT01072773 | Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01233921 | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | completed | N/A | 6 | Martin, PaulOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 133 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 31, 2014 | clinicaltrials |
| NCT02095379 | Oligosecretary Myeloma: Prevalence and Its Clinical Significance | completed | — | 390 | Samsung Medical CenterOTHER | 1 | Mar 24, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00103662 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients | completed | Phase 3 | 302 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Mar 13, 2014 | clinicaltrials |
| NCT00322387 | Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322491 | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322842 | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00218855 | Thalidomide to Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 363 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00396266 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00791011 | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | completed | Phase 1 | 33 | AmgenINDUSTRY | 0 | Mar 5, 2014 | clinicaltrials |
| NCT00970021 | Agaricus Blazei Murill in Patients With Multiple Myeloma | completed | Phase 2 | 39 | Ullevaal University HospitalOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT02060435 | Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma | completed | — | 571 | Samsung Medical CenterOTHER | 1 | Feb 12, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT01022255 | Autologous Vaccine for Follicular Lymphoma | completed | Phase 1 | 28 | Icon Genetics GmbHINDUSTRY | 1 | Jan 30, 2014 | clinicaltrials |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | completed | Phase 2 | 116 | GlaxoSmithKlineINDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma(P05538) | completed | Phase 1 | 41 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 2 | 57 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00440765 | VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands | completed | — | 331 | Janssen-Cilag B.V.INDUSTRY | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT01543100 | Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy(PACMoG) | completed | N/A | 60 | Rennes University HospitalOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00656812 | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT00985959 | A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) | completed | Phase 1 | 101 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT01998503 | Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | completed | Phase 3 | 56 | Nanjing University School of MedicineOTHER | 1 | Nov 29, 2013 | clinicaltrials |
| NCT00373906 | Velcade in MALT Lymphoma Patients | completed | Phase 2 | 16 | Medical University of ViennaOTHER | 0 | Nov 27, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2014source: clinicaltrials